CN113563319B - 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 - Google Patents
具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 Download PDFInfo
- Publication number
- CN113563319B CN113563319B CN202110813592.9A CN202110813592A CN113563319B CN 113563319 B CN113563319 B CN 113563319B CN 202110813592 A CN202110813592 A CN 202110813592A CN 113563319 B CN113563319 B CN 113563319B
- Authority
- CN
- China
- Prior art keywords
- mmol
- monosubstituted
- disease
- benzyl
- carboxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Indazole heterocyclic compounds Chemical class 0.000 title claims description 32
- 230000002401 inhibitory effect Effects 0.000 title abstract description 12
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 title description 6
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 title description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 claims abstract description 13
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 3
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 3
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 3
- 239000002249 anxiolytic agent Substances 0.000 claims abstract description 3
- 230000000949 anxiolytic effect Effects 0.000 claims abstract description 3
- 208000006673 asthma Diseases 0.000 claims abstract description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 230000019771 cognition Effects 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 8
- 230000002757 inflammatory effect Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000007370 cognitive improvement Effects 0.000 abstract description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 36
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 239000007858 starting material Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IHDCMMYSCOPPRA-UHFFFAOYSA-N CC(C)N1N=C(C(S2)=CC=C2Cl)C2=CC(NCCC(O)=O)=CC=C12 Chemical compound CC(C)N1N=C(C(S2)=CC=C2Cl)C2=CC(NCCC(O)=O)=CC=C12 IHDCMMYSCOPPRA-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- JEINGJKDOKBDKK-UHFFFAOYSA-N CC(C)N1N=C(C(S2)=CC=C2Cl)C2=CC(NC(C3(CC3)C(O)=O)=O)=CC=C12 Chemical compound CC(C)N1N=C(C(S2)=CC=C2Cl)C2=CC(NC(C3(CC3)C(O)=O)=O)=CC=C12 JEINGJKDOKBDKK-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- LMMAMJOYDNFXOM-UHFFFAOYSA-N OC(CCNC1=CC=C2N(CC(F)F)N=C(C(S3)=CC=C3Cl)C2=C1)=O Chemical compound OC(CCNC1=CC=C2N(CC(F)F)N=C(C(S3)=CC=C3Cl)C2=C1)=O LMMAMJOYDNFXOM-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 239000000168 bronchodilator agent Substances 0.000 description 3
- 108020001778 catalytic domains Proteins 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- JFCLNCVCDFUJPO-UHFFFAOYSA-N (5-chlorothiophen-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)S1 JFCLNCVCDFUJPO-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 2
- SYTGRKBQTUKOAI-UHFFFAOYSA-N 3-bromo-5-nitro-2h-indazole Chemical compound C1=C([N+](=O)[O-])C=CC2=NNC(Br)=C21 SYTGRKBQTUKOAI-UHFFFAOYSA-N 0.000 description 2
- LFPDNJIYHHSUNL-UHFFFAOYSA-N CC(C)N(C(C1=C2)=CC=C2NCCC(O)=O)N=C1C1=CC(Cl)=CC=C1 Chemical compound CC(C)N(C(C1=C2)=CC=C2NCCC(O)=O)N=C1C1=CC(Cl)=CC=C1 LFPDNJIYHHSUNL-UHFFFAOYSA-N 0.000 description 2
- YENPQYIMVAOXLS-UHFFFAOYSA-N CC(C)N1N=C(C(S2)=CC=C2Cl)C2=CC(NC(C)CC(O)=O)=CC=C12 Chemical compound CC(C)N1N=C(C(S2)=CC=C2Cl)C2=CC(NC(C)CC(O)=O)=CC=C12 YENPQYIMVAOXLS-UHFFFAOYSA-N 0.000 description 2
- QYJVYWQVNMZDED-UHFFFAOYSA-N CC(C)N1N=C(C(S2)=CC=C2Cl)C2=CC(NCC(C)C(O)=O)=CC=C12 Chemical compound CC(C)N1N=C(C(S2)=CC=C2Cl)C2=CC(NCC(C)C(O)=O)=CC=C12 QYJVYWQVNMZDED-UHFFFAOYSA-N 0.000 description 2
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QSUUZGTWTQWPMA-UHFFFAOYSA-N OC(C1(CC1)C(NC1=CC=C2N(CC(F)F)N=C(C(S3)=CC=C3Cl)C2=C1)=O)=O Chemical compound OC(C1(CC1)C(NC1=CC=C2N(CC(F)F)N=C(C(S3)=CC=C3Cl)C2=C1)=O)=O QSUUZGTWTQWPMA-UHFFFAOYSA-N 0.000 description 2
- LFBCXDNYFWVJFM-UHFFFAOYSA-N OC(CCN1N=C(C(S2)=CC=C2Cl)C2=CC(NCC(O)=O)=CC=C12)=O Chemical compound OC(CCN1N=C(C(S2)=CC=C2Cl)C2=CC(NCC(O)=O)=CC=C12)=O LFBCXDNYFWVJFM-UHFFFAOYSA-N 0.000 description 2
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 108700025647 major vault Proteins 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
- 229950005741 rolipram Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VMFCTZUYOILUMY-UHFFFAOYSA-N 1,1-difluoro-2-iodoethane Chemical compound FC(F)CI VMFCTZUYOILUMY-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- AGPZPJHWVWZCMG-UHFFFAOYSA-N 2-(4-formylphenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(C=O)C=C1 AGPZPJHWVWZCMG-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-M 3',5'-cyclic AMP(1-) Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-M 0.000 description 1
- CBYFWCPHCZJWKC-UHFFFAOYSA-N 3-(5-chlorothiophen-2-yl)-1-(2,2-difluoroethyl)-5-nitroindazole Chemical compound C1=CC2=C(C=C1[N+](=O)[O-])C(=NN2CC(F)F)C3=CC=C(S3)Cl CBYFWCPHCZJWKC-UHFFFAOYSA-N 0.000 description 1
- IFIIRUBFXPIOMX-UHFFFAOYSA-N 3-(5-chlorothiophen-2-yl)-1-(2,2-difluoroethyl)indazol-5-amine Chemical compound C1=CC2=C(C=C1N)C(=NN2CC(F)F)C3=CC=C(S3)Cl IFIIRUBFXPIOMX-UHFFFAOYSA-N 0.000 description 1
- VSQDJEZFFOTWRV-UHFFFAOYSA-N 3-(5-chlorothiophen-2-yl)-1-propan-2-ylindazol-5-amine Chemical compound CC(C)N1C2=C(C=C(C=C2)N)C(=N1)C3=CC=C(S3)Cl VSQDJEZFFOTWRV-UHFFFAOYSA-N 0.000 description 1
- BBXXMSBCIXEKJZ-UHFFFAOYSA-N 3-(5-chlorothiophen-2-yl)-5-nitro-1-propan-2-ylindazole Chemical compound CC(C)N1C2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=C(S3)Cl BBXXMSBCIXEKJZ-UHFFFAOYSA-N 0.000 description 1
- HIYFAOFRKIAFBW-UHFFFAOYSA-N 3-bromo-1-(2,2-difluoroethyl)-5-nitroindazole Chemical compound C1=CC2=C(C=C1[N+](=O)[O-])C(=NN2CC(F)F)Br HIYFAOFRKIAFBW-UHFFFAOYSA-N 0.000 description 1
- YKBMBIFCTGFATI-UHFFFAOYSA-N 3-bromo-5-nitro-1-propan-2-ylindazole Chemical compound N1=C(C2=C(N1C(C)C)C=CC(N(=O)=O)=C2)Br YKBMBIFCTGFATI-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- ZFDCWHPNBWPPHG-UHFFFAOYSA-N ethyl 2-(4-bromophenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(Br)C=C1 ZFDCWHPNBWPPHG-UHFFFAOYSA-N 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- QBGQCRUYARHQGO-UHFFFAOYSA-N methyl 2-(4-bromo-2-fluorophenyl)acetate Chemical compound COC(=O)CC1=CC=C(Br)C=C1F QBGQCRUYARHQGO-UHFFFAOYSA-N 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940125391 short-acting muscarinic receptor antagonist Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
本发明公开了一类含有吲唑杂环骨架的化合物及其应用,属于药物化学领域。所述含有吲唑杂环骨架的化合物对PDE4B具有较好的抑制活性,可作为PDE4B抑制剂,用于制备预防或治疗与PDE4B相关疾病的药物,包括慢性阻塞性肺病、哮喘、皮炎、银屑病等炎症相关疾病的药物以及阿兹海默症、抗焦虑、改善认知等中枢神经疾病的药物。
Description
技术领域
本发明属于药物化学技术领域,具体涉及一种具有磷酸二酯酶4B抑制活性的吲唑杂环类化合物。
背景技术
慢性阻塞性肺病(chronic obstructive pulmonary disease,COPD)是一种常见的、可以预防和治疗的疾病,以持续呼吸症状和气流受限为特征,通常是由于明显暴露于有毒颗粒或气体引起的气道和/或肺泡异常所导致。目前,COPD是世界上第四位的致死病,每年有超过300万的人死于COPD,约占全球死亡数的6%(Global initiative for chronicobstructive lung disease,updated 2019)。根据最新统计,慢阻肺已经成为我国第三大慢性病,仅次于高血压、糖尿病,约有1亿的慢阻肺患者(Lancet.2018;391(10131):1706-1717)。随着空气污染、人口老龄化不断加剧,COPD患病率近年来持续增加,不仅给病人带来长期的痛苦折磨,还会给家庭、社会带来沉重的经济负担。
目前临床上常用的慢阻肺治疗药物,根据其药理活性可以分为支气管扩张剂和抗炎药。其中支气管扩张剂占主导地位,包括长效和短效的毒蕈碱样受体拮抗剂如异丙托溴铵、噻托溴铵,长效和短效的β2-肾上腺素受体激动剂,还有支气管扩张剂与抗炎类糖皮质激素等联合用药。但是,这些治疗方案只能改善COPD症状、减少急性加重率以及降低病死率,对COPD的症状起缓解作用,不能根治,导致肺功能不可避免的持续下降。因此,临床上对于COPD特效治疗药物迫切需求,研究和发现新型COPD治疗药物仍是目前的热点。
由于COPD是一种复杂的、综合性的疾病,发病过程中涉及多种机制,包括炎症反应、氧化应激、线粒体功能异常、衰老、蛋白酶-抗蛋白酶失衡等机制,这些机制相互联系、互相作用,构成了COPD的复杂性、持续性、难治性。针对COPD的炎症机制进行了深入的研究和开发。磷酸二酯酶4(Phosphodiesterase 4,PDE4)广泛表达于各种炎症和免疫细胞中,可以特异性水解环磷酸腺苷(Cyclic 3’,5’-adenosine monophosphate,cAMP),在炎症反应中扮演重要的角色。PDE4抑制剂主要通过抑制PDE4水解作用,增加体内cAMP水平,抑制炎症因子的释放,同时促进抗炎介质的产生,发挥抗炎作用。Roflumilast在临床上用于治疗COPD,抗炎作用显著,可以抑制单核细胞、巨噬细胞及T细胞等释放TNF-α、白介素、趋化因子等炎症介质。但这类抑制剂普遍存在恶心、呕吐等严重的副作用,限制了PDE4抑制剂的临床应用。大量研究表明,在人体内,磷酸二酯酶4的亚型B(PDE4B)与炎症反应相关,参与体内各种炎症介质的释放,而亚型D与恶心、呕吐等副作用的产生密切相关,这为发现副作用低的PDE4抑制剂提供了新的思路,即设计PDE4B抑制剂可能会减少副作用的影响,促进进一步的临床应用。
PDE4的四个亚型催化域的蛋白序列具有高度的同源性,作用于催化域的抑制剂不会产生亚型选择性,而大部分已报道经典的PDE4抑制剂是作用于催化域的。近几年报道的新的PDE4抑制剂作用模式,抑制剂同时与催化域和调控序列作用,使调控序列能够稳定蛋白的封闭构象,阻止cAMP进入,发挥抑制作用。
据此,本发明针对调控序列CR3展开了对PDE4B抑制剂的设计合成研究,设计并合成了一类具有PDE4B抑制活性的化合物。
发明内容
本发明的目的是提供一类含有吲唑杂环骨架的具有磷酸二酯酶4B抑制活性的化合物及其应用。
为了实现上述发明目的,本发明采用以下技术上方案:
一种取代的吲唑杂环类化合物,为式I所示的化合物或其旋光异构体、对映体、非对映体、外消旋体、外消旋混合物,或其药学上可接受的盐或前药,
其中:
R1选自C1-C6烷基、C2-C6烯基、C2-C6羧基、C1-C3二氟甲基、C1-C3三氟甲基或取代苄基中的一种,所述取代苄基中苄基的取代基选自F、Cl、Br、I、CF3、CN、羟基、甲氧基、甲基、氨基、硝基、巯基、羧基、乙烯基、C4-C8直链烷基或支链烷基、芳基、杂环基;
R2为芳基或杂环芳基,所述芳基选自无取代、单取代或多取代的苯基、萘基或联苯基,单取代或多取代的取代基选自卤素、氰基、硝基、羟基、氨基、羧基、甲酯基或乙酯基,所述杂环芳基选自无取代、单取代或多取代的嘧啶、咪唑、吡唑、吡啶、三唑、噻唑、噻吩、吲哚、吲唑或苯并咪唑,单取代或多取代的取代基选自卤素、氰基、硝基、羟基、氨基、羧基、甲酯基或乙酯基;
W、X、Y选自C、N、O或S,Z为C或N,X取代基位置选自W的邻位、对位或间位;
R3选自C1-C6烷基、C2-C6羧基、苯基、杂环芳基或苄基,所述苯基、杂环芳基、苄基为无取代、单取代或双取代,单取代或双取代的取代基选自F、Cl、Br、I、CF3、CN、羟基、甲氧基、甲基、氨基、硝基、巯基、羧基、乙烯基、C4-C8直链烷基或支链烷基、芳基、杂环基。
进一步地,所述化合物选自以下化合物:
上述化合物作为PDE4B抑制剂在制备预防和/或治疗与PDE4B相关疾病的药物中的应用。
所述PDE4B相关疾病包括炎症疾病和中枢神经疾病。
所述炎症疾病包括慢性阻塞性肺病、哮喘、皮炎、银屑病;所述中枢神经疾病包括阿兹海默症、抗焦虑、改善认知。
本发明通过现代药理科学研究,证实了该取代的吲唑杂环类化合物对PDE4B具有较好的抑制活性,并适用于与PDE4B相关的疾病。
附图说明
图1为实施例中化合物的TNF-a抑制活性。
具体实施方式
为了进一步阐明本发明,下面给出一系列实施例,这些实施例完全是例证性的,它们仅用来对本发明具体描述,不应当理解为对本发明的限制。
实施例1
制备3-((3-(5-氯噻吩-2-基)-1-异丙基-1H-吲唑-5-基)氨基)丙酸(I-1)
步骤1.合成3-溴-1-异丙基-5-硝基-1H-吲唑
取1.00g(4.14mmol)3-溴-5-硝基-1H-吲唑和331.2mg(8.28mmol)氢化钠(含量60%)加入250mL茄形瓶中,在冰浴条件下加入120mL无水N,N-二甲基甲酰胺溶解,搅拌0.5h后移至室温,加入446μL(4.54mmol)2-碘代丙烷,室温搅拌反应24h。向反应液中加入3倍体积的水进行淬灭,用乙酸乙酯萃取多次,合并有机相,再用水洗2次,有机相用无水硫酸钠干燥。有机相浓缩后制砂,柱层析纯化(石油醚:二氯甲烷=4:1),得到白色固体435mg,收率为41.4%。
1H-NMR(500MHz,DMSO-d6):δ8.44(d,1H),8.28(dd,J=9.3,2.0Hz,1H),8.02(d,J=9.3Hz,1H),5.14(m,1H),1.51(d,J=6.6Hz,6H).
步骤2.合成3-(5-氯噻吩-2-基)-1-异丙基-5-硝基-1H-吲唑
取510.0mg(2.00mmol)原料置于50mL两颈圆底烧瓶中,加入486.0mg(3.00mmol)5-氯噻吩-2-硼酸和37.0mg(0.05mmol)[1,1'-双(二苯基膦基)二茂铁]二氯化钯(Pd(dppf)Cl2),用甲苯16mL及8mL甲醇溶解,再加入Na2CO3 424mg(4.00mmol),水泵抽真空10min,氮气保护,110℃回流。反应约14h后TLC检测原料已反应完。反应液抽滤,滤液制砂,柱层析纯化(石油醚:二氯甲烷=8:1)得到黄色固体295mg,收率为46.0%。
1H-NMR(400MHz,CDCl3):δ8.91(dd,J=2.1,0.6Hz,1H),8.29(dd,J=9.3,2.1Hz,1H),7.50(d,J=9.3Hz,1H),7.44(d,J=3.9Hz,1H),7.02(d,J=3.9Hz,1H),4.88(m,1H),1.64(d,J=6.7Hz,6H).
步骤3.合成3-(5-氯噻吩-2-基)-1-异丙基-1H-吲唑-5-胺
取200mg(0.80mmol)原料置于100mL茄形瓶中,加入148mg(2.64mmol)还原铁粉和353mg(6.60mmol)氯化铵,用乙醇8mL、水4mL溶解后置于80℃反应约1h。TLC检测原料已完全还原,过滤不溶性杂质,滤液用二氯甲烷萃取3次,合并有机相,无水硫酸钠干燥后浓缩,干燥,称重,粗产品约165mg,收率约90%。
步骤4.合成3-((3-(5-氯噻吩-2-基)-1-异丙基-1H-吲唑-5-基)氨基)丙酸(I-1)
取上一步粗产品165mg置于10mL圆底烧瓶中,加入45μL(0.66mmol)丙烯酸,4mL甲苯溶解,110℃搅拌回流反应。反应24h后,TLC检测原料部分剩余,停止反应。将反应液转移至100mL茄形瓶中,加入6mL甲苯稀释,再加入大量稀氢氧化钠溶液,将反应液调PH至碱性,搅拌均匀后静置分层,取下层水相。水相用甲苯洗2次,乙醚洗2次。向水相中加入15%稀盐酸,调节PH至5-6,水相变浑浊,乙酸乙酯萃取3次,合并有机相,无水硫酸钠干燥,浓缩后重结晶得固体约30mg,收率约12.5%。
M.P.165-168℃,1H-NMR(300MHz,DMSO-d6):δ7.50(d,J=9.0Hz,1H),7.43(d,J=3.9Hz,1H),7.17(d,J=3.9Hz,1H),6.91(d,J=9.1Hz,1H),6.84(s,1H),4.87(m,1H),3.33(t,J=7.0Hz,2H),2.56(t,J=6.6Hz,2H),1.46(d,J=6.6Hz,6H).
实施例2
制备3-((3-(5-氯噻吩-2-基)-1-异丙基-1H-吲唑-5-基)氨基)丁酸(I-2)
参照I-1的合成方法,得到固体约16mg,收率约12.8%。
M.P.170-172℃,1H-NMR(300MHz,DMSO-d6):δ8.07–7.62(m,2H),7.38(d,J=3.7Hz,2H),7.13(d,J=3.8Hz,1H),4.89(dt,J=12.8,6.1Hz,1H),3.85(s,1H),2.68(d,J=15.8Hz,1H),2.55–2.40(m,1H),1.37(d,J=6.4Hz,6H),1.20(d,J=5.9Hz,3H);ESI-MS(m/z):378.1[M+H]+,376.1[M-H]-.
实施例3
制备3-((3-(5-氯噻吩-2-基)-1-异丙基-1H-吲唑-5-基)氨基)-2-甲基丙酸(I-3)
参照I-1的合成方法,得到固体约9mg,收率约7.2%。
M.P.170-174℃,1H-NMR(300MHz,DMSO-d6):δ7.50(d,J=9.0Hz,1H),7.42(d,J=3.8Hz,1H),7.16(d,J=3.8Hz,1H),6.94(d,J=9.1Hz,1H),6.87(s,1H),4.87(m,1H),3.51(s,1H),3.11(dd,J=12.7,6.3Hz,1H),2.71(dd,J=12.9,6.5Hz,1H),1.46(d,J=6.5Hz,6H),1.24(d,J=9.2Hz,3H);ESI-MS(m/z):378.2[M+H]+,376.2[M-H]-.
实施例4
制备(3-(5-氯噻吩-2-基)-1-异丙基-1H-吲唑-5-基)甘氨酸(I-4)
步骤a.合成(3-(5-氯噻吩-2-基)-1-异丙基-1H-吲唑-5-基)甘氨酸乙酯
取粗产品约190mg置于15mL圆底烧瓶中,加入65mg(0,79mmol)醋酸钠、83μL(0.79mmol)氯乙酸乙酯,加入6mL乙醇溶解,120℃搅拌加热反应。反应24h后TLC检测原料仍有剩余,停止反应。反应液旋干后制砂,柱层析纯化(石油醚:乙酸乙酯=16:1和8:1)得到淡黄色固体120mg,收率为48.1%。
步骤b.合成(3-(5-氯噻吩-2-基)-1-异丙基-1H-吲唑-5-基)甘氨酸(I-4)
向15mL圆底烧瓶中加入120mg(0.32mmol)原料、60mg(1.28mmol)氢氧化钠,用3mL甲醇、2mL水溶解,50℃加热搅拌。反应2h后TLC检测原料已水解完。加15%稀盐酸调PH至中性,有固体析出,过滤得,再次溶解后重结晶得纯品约20mg,收率为17.9%。
M.P.130-133℃,1H-NMR(300MHz,DMSO-d6):δ7.52(d,J=9.1Hz,1H),7.41(d,J=3.9Hz,1H),7.18(d,J=3.9Hz,1H),6.99(dd,J=9.0,2.0Hz,1H),6.80(d,J=1.7Hz,1H),4.88(m,1H),3.92(s,2H),1.46(d,J=6.6Hz,6H);ESI-MS(m/z):348.1[M-H]-.
实施例5
制备1-((3-(5-氯噻吩-2-基)-1-异丙基-1H-吲唑-5-基)氨基甲酰基)环丙烷-1-羧酸(I-5)
步骤a.合成1-((3-(5-氯噻吩-2-基)-1-异丙基-1H-吲唑-5-基)氨基甲酰基)环丙烷-1-羧酸(I-5)
向50mL圆底烧瓶中加入22mg(0.165mmol)1,1-二环丙基二羧酸和23μL(0.165mmol)三乙胺,无水四氢呋喃溶解,冰浴下搅拌反应0.5h。缓慢加入氯化亚砜12μL(0.165mmol),继续反应0.5h。缓慢滴加无水四氢呋喃溶解的原料48mg(0.165mmol),反应2h。TLC检测原料反应完全,将反应液旋干,加入甲苯溶解,再加入大量稀氢氧化钠溶液,将反应液调PH至碱性,搅拌均匀后静置分层,取下层水相。水相用甲苯洗2次,乙醚洗2次。向水相中加入15%稀盐酸,调节PH至5-6,水相变浑浊,乙酸乙酯萃取3次,合并有机相,无水硫酸钠干燥,浓缩后重结晶得固体约25mg,收率为37.5%。
M.P.140-144℃,1H-NMR(300MHz,DMSO-d6):δ10.74(s,1H),8.46(s,1H),7.74(d,J=9.1Hz,1H),7.56(dd,J=9.1,1.5Hz,1H),7.40(d,J=3.9Hz,1H),7.23(d,J=3.9Hz,1H),4.99(m,1H),1.48(m,10H);ESI-MS(m/z):402.1[M-H]-.
实施例6
制备3-((3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)氨基)丙酸(I-6)
步骤a.合成3-溴-1-(2,2-二氟乙基)-5-硝基-1H-吲唑
取1.00g(4.14mmol)3-溴-5-硝基-1H-吲唑、273μL(6.20mmol)1,1-二氟-2-碘乙烷以及1.14g(8.26mmol)碳酸钾置于250mL茄形瓶中,用100mL无水乙腈溶解,回流搅拌,反应24h。TLC检测原料基本反应完,反应液过滤后直接制砂,柱层析纯化(石油醚:二氯甲烷=4:1)得到淡黄色固体约850mg,收率为67.1%。
1H-NMR(300MHz,Chloroform-d):δ8.63(dd,J=2.1,0.6Hz,1H),8.38(dd,J=9.3,2.1Hz,1H),7.55(d,J=9.3Hz,1H),6.19(tt,J=55.1,4.2Hz,1H),4.75(td,J=13.4,4.2Hz,2H).
步骤b.合成3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-5-硝基-1H-吲唑
取486.0mg原料置于50mL两颈圆底烧瓶中,加入386.0mg(2.38mmol)5-氯噻吩-2-硼酸、337mg(3.18mmol)碳酸钠和35.0mg(0.05mmol)[1,1'-双(二苯基膦基)二茂铁]二氯化钯(Pd(dppf)Cl2),用甲苯16mL及甲醇8mL溶解,再加入Na2CO3 337mg(3.18mmol),水泵抽真空10min,氮气保护,110℃回流。反应约20h后TLC检测原料已反应完。反应液抽滤,滤液制砂,柱层析纯化(石油醚:二氯甲烷=8:1),得固体约得到黄色固体200mg,收率为36.7%。
1H-NMR(300MHz,Chloroform-d):δ8.63(dd,J=2.1,0.6Hz,1H),8.38(dd,J=9.3,2.1Hz,1H),7.55(d,J=9.3Hz,1H),6.19(tt,J=55.1,4.2Hz,1H),4.75(td,J=13.4,4.2Hz,2H).
步骤c.合成3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-1H-吲唑-5-胺
/>
取100mg(0.30mmol)上述原料置于100mL茄形瓶中,加入67mg(1.20mmol)还原铁粉和214mg(4.0mmol)氯化铵,用乙醇8mL、水4mL溶解后置于80℃反应约1h。TLC检测原料已完全还原,过滤不溶性杂质,滤液用二氯甲烷萃取3次,合并有机相,无水硫酸钠干燥后浓缩,干燥,称重,粗产品约85mg,收率约90%。
步骤d.合成3-((3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)氨基)丙酸(I-6)
取上一步粗产品85mg置于10mL圆底烧瓶中,加入18μL(0.27mmol)丙烯酸,4mL甲苯溶解,110℃搅拌回流反应。反应24h后,TLC检测原料部分剩余,停止反应。将反应液转移至100mL茄形瓶中,加入6mL甲苯稀释,再加入大量稀氢氧化钠溶液,将反应液调PH至碱性,搅拌均匀后静置分层,取下层水相。水相用甲苯洗2次,乙醚洗2次。向水相中加入15%稀盐酸,调节PH至5-6,水相变浑浊,乙酸乙酯萃取3次,合并有机相,无水硫酸钠干燥,浓缩后重结晶得固体约10mg,收率约9.0%。
M.P.180-182℃1H-NMR(300MHz,DMSO-d6):δ7.57–7.48(m,2H),7.20(d,J=3.9Hz,1H),6.96(d,J=9.1Hz,1H),6.87(s,1H),6.40(tt,J=54.9,3.6Hz,1H),4.86(td,J=15.0,2.9Hz,2H),3.32(s,2H),2.56(t,J=6.6Hz,2H);ESI-MS(m/z):386.1[M+H]+,384.0[M-H]-.
实施例7
制备3-((3-(5-氯噻吩-2-基)-1-(2,2,2-三氟乙基)-1H-吲唑-5-基)氨基)丙酸(I-7)
参照I-6的合成方法,得固体约11mg,收率约9.7%。
M.P.168-170℃1H-NMR(300MHz,DMSO-d6)δ7.64–7.54(m,2H),7.22(d,J=3.9Hz,1H),7.02(dd,J=9.1,1.7Hz,1H),6.94(s,1H),5.40(q,J=9.1Hz,2H),3.36(t,J=6.7Hz,2H),2.57(t,J=6.7Hz,2H);ESI-MS(m/z):404.2[M+H]+,402.1[M-H]-.
实施例8
制备3-((3-(5-氯噻吩-2-基)-1-异丙基-1H-吲唑-5-基)氨基)丙酸(I-8)
参照I-1的合成方法,得固体约25mg,收率约13.8%。
M.P.164-166℃,1H-NMR(300MHz,DMSO-d6):δ7.66(d,J=9.0Hz,1H),7.51(d,J=3.9Hz,1H),7.41(s,1H),7.22(m,2H),4.42(q,J=7.1Hz,2H),3.45(t,J=6.9Hz,2H),2.65(t,J=6.9Hz,2H),1.39(t,J=7.2Hz,3H);ESI-MS(m/z):350.2[M+H]+,348.1[M-H]-.
实施例9
制备3-((3-(3-氯苯基)-1-异丙基-1H-吲唑-5-基)氨基)丙酸(I-9)
参照I-1的合成方法,得到固体约28mg,收率约15.1%。
M.P.170-171℃1H-NMR(300MHz,DMSO-d6):δ7.97–7.77(m,4H),7.58(t,J=8.0Hz,1H),7.52–7.45(m,1H),7.41(d,J=8.3Hz,1H),5.07(p,J=6.5Hz,1H),3.52(t,J=7.0Hz,2H),2.71(t,J=7.0Hz,2H),1.54(d,J=6.6Hz,6H);ESI-MS(m/z):358.2[M+H]+,356.2[M-H]-.
实施例10
制备(3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)甘氨酸(I-10)
参照I-4的合成方法,得到固体约24mg收率为25.9%。
M.P.173-175℃,1H-NMR(300MHz,DMSO-d6):δ7.64(d,J=9.2Hz,1H),7.54(d,J=3.5Hz,1H),7.22(d,J=8.3Hz,3H),6.42(t,J=54.7Hz,1H),4.91(t,J=15.0Hz,2H),4.07(s,2H).
实施例11
制备3-(5-((羧甲基)氨基)-3-(5-氯噻吩-2-基)-1H-吲唑-1-基)丙酸(I-11)
参照I-4的合成方法,得到固体约30mg,收率为28.2%。
M.P.111-115℃,1H-NMR(300MHz,DMSO-d6):δ7.67(dd,J=9.0,4.1Hz,1H),7.51(d,J=4.0Hz,1H),7.41(d,J=10.0Hz,1H),7.29(d,J=9.0Hz,1H),7.23(d,J=3.9Hz,1H),4.61(t,J=6.5Hz,2H),4.12(s,2H),2.93(t,J=6.5Hz,2H).
实施例12
制备(3-(5-氯噻吩-2-基)-1-(3-(甲氧羰基)苄基)-1H-吲唑-5-基)甘氨酸(I-12)
参照I-4的合成方法,得到固体约30mg,收率为24.8%。
1H-NMR(300MHz,DMSO-d6):δ7.84(d,J=8.3Hz,2H),7.70(d,J=9.1Hz,1H),7.54(d,J=4.0Hz,1H),7.46(dd,J=4.6,1.9Hz,2H),7.39(s,1H),7.26(dd,J=9.8,2.6Hz,2H),5.73(s,2H),4.11(s,2H);HRMS(ESI-TOF):called for C21H16ClN3O4S[M+H]+442.0550,found442.0627.
实施例13
制备1-((3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)氨基甲酰基)环丙烷-1-甲酸(I-13)
参照I-5的合成方法,得到固体约30mg,收率为25.8%。
M.P.152-155℃,1H-NMR(300MHz,DMSO-d6):δ10.76(s,1H),8.54–8.46(m,1H),7.76(d,J=9.1Hz,1H),7.62(dd,J=9.1,1.8Hz,1H),7.47(d,J=4.0Hz,1H),7.27(d,J=3.9Hz,1H),6.46(tt,J=54.7,3.4Hz,1H),4.97(td,J=15.2,3.2Hz,2H),1.47(d,J=3.2Hz,4H);HRMS(ESI-TOF):called for C18H14ClF2N3O3S[M+H]+426.0412,found 426.0487.
实施例14
制备1-(3-(3-氯苯基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)-5-氧代吡咯烷-3-羧酸(I-14)
参照I-6的合成方法,得到固体约28mg,收率为21.9%。
M.P.174-178℃,1H NMR(400MHz,DMSO-d6):δ12.62(s,1H),8.17(s,1H),7.94–7.93(m,2H),7.83(d,J=1.6Hz,2H),7.59(t,J=8.1Hz,1H),7.53–7.50(m,1H),6.51(tt,J=54.7,3.5Hz,1H),5.03(td,J=15.2,3.4Hz,2H),4.21–4.09(m,2H),3.40(tt,J=8.9,4.9Hz,1H),2.84–2.71(m,2H).HRMS(ESI-TOF):called for C20H16ClF2N3O3[M+H]+420.0848,found 420.0980.
实施例15
制备2-(4-(((3-(3-氯苯基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)氨基)甲基)苯基)乙酸(I-15)
步骤a.合成2-(4-(((3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)氨基)甲基)苯基)乙酸(I-15)
取粗产品100mg置于10ml圆底烧瓶中,加入42mg(0.26mmol)2-(4-甲酰基苯基)乙酸、97mg(0.38mmol)二氢吡啶和21ul(0.28mmol)三氟乙酸,以及适量分子筛,5ml二氯甲烷溶解,45℃搅拌回流反应。反应12h后,TLC检测原料已反应完,停止反应。将反应液抽滤,滤液制砂,柱层析纯化(二氯甲烷:甲醇=100:1),约得到淡黄色固体30mg,收率为20.4%。
M.P.134-136℃,1H NMR(400MHz,DMSO-d6):δ12.27(s,1H),7.79–7.78(m,1H),7.76(d,J=7.9Hz,1H),7.54–7.50(m,2H),7.43(ddd,J=8.0,2.0,0.9Hz,1H),7.38(d,J=8.0Hz,2H),7.23(d,J=8.0Hz,2H),7.02(dd,J=9.1,1.9Hz,1H),6.87(d,J=1.6Hz,1H),6.43(tt,J=54.8,3.6Hz,2H),4.87(td,J=15.0,3.5Hz,2H),4.32(s,2H),3.53(s,2H).HRMS(ESI-TOF):called for C24H20ClF2N3O2[M+H]+456.1212,found 456.1295.
实施例16
制备4-((3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)氨基)苯乙酸(I-16)
步骤a.合成2-(4-((3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)氨基)苯基)乙酸乙酯
取粗产品150mg置于25ml两颈瓶中,加入97mg(0.40mmol)对溴苯乙酸乙酯,5ml甲苯溶解,再加入261mg(0.80mmol)碳酸铯、9mg(0.04mmol)醋酸钯以及50mg(0.08mmol)BINAP,体系抽真空,氮气保护,120℃搅拌回流反应。反应24h后,TLC检测原料已反应完,停止反应。将反应液旋干,直接制砂,柱层析纯化(石油醚:乙酸乙酯=8:1),得到棕色油状物约55mg,收率29.0%。
步骤b.合成4-((3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)氨基)苯乙酸(I-16)
向15ml圆底烧瓶中加入100mg(0.21mmol)原料、47mg(0.84mmol)氢氧化钾,用3ml甲醇、2ml水溶解,100℃加热搅拌。反应2h后TLC检测原料已水解完。加15%稀盐酸调PH至中性,有固体析出,乙酸乙酯萃取3次,合并有机相,无水硫酸钠干燥,浓缩后重结晶得固体约27mg,收率约28.7%。
M.P.119-122℃,1H NMR(400MHz,DMSO-d6):δ12.23(s,1H),8.20(s,1H),7.70(d,J=9.0Hz,1H),7.61(s,1H),7.44(d,J=3.9Hz,1H),7.32–7.29(m,1H),7.22(d,J=3.8Hz,1H),7.13(d,J=8.3Hz,2H),7.03(d,J=8.3Hz,2H),6.45(tt,J=54.6,3.0Hz,1H),4.94(td,J=15.1,2.9Hz,2H),3.46(s,2H).HRMS(ESI-TOF):called for C21H16ClF2N3O2S[M+H]+448.0620,found448.0733.
实施例17
制备2-(5-((3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)氨基)吡啶-2-基)乙酸(I-17)
参照I-16的合成方法,得到固体约21mg,收率为23.1%。
M.P.115-118℃,1H NMR(400MHz,DMSO-d6):δ12.32(s,1H),8.41(s,1H),8.27(d,J=2.8Hz,1H),7.74(d,J=9.0Hz,1H),7.65(d,J=2.0Hz,1H),7.47(dd,J=11.1,3.4Hz,2H),7.34–7.31(m,1H),7.23–7.20(m,2H),6.46(tt,J=54.7,3.6Hz,1H),4.95(td,J=15.3,3.6Hz,2H),3.65(s,2H).HRMS(ESI-TOF):called for C20H15ClF2N4O2S[M+H]+449.0572,found 449.0832.
实施例18
制备2-(4-((3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)氨基)-2-氟苯基)乙酸甲酯(I-18)
步骤a.合成2-(4-((3-(5-氯噻吩-2-基)-1-(2,2-二氟乙基)-1H-吲唑-5-基)氨基)-2-氟苯基)乙酸甲酯(I-18)
取粗产品150mg置于25ml两颈瓶中,加入107mg(0.43mmol)2-(4-溴-2-氟苯基)乙酸甲酯,5ml甲苯溶解,再加入312mg(0.96mmol)碳酸铯、22mg(0.1mmol)醋酸钯以及125mg(0.2mmol)BINAP,体系抽真空,氮气保护,120℃搅拌回流反应。反应24h后,TLC检测原料已反应完,停止反应。将反应液旋干,直接制砂,柱层析纯化(石油醚:乙酸乙酯=8:1),得到棕色油状物约35mg,收率22.4%。
1H NMR(400MHz,DMSO-d6):δ8.43(s,1H),7.75–7.72(m,1H),7.68(d,J=1.7Hz,1H),7.49(d,J=4.0Hz,1H),7.35(dd,J=9.0,2.0Hz,1H),7.22(d,J=3.9Hz,1H),7.18–7.13(m,1H),6.82(dd,J=8.3,2.1Hz,1H),6.76(dd,J=12.5,2.1Hz,1H),6.46(tt,J=54.7,3.5Hz,1H),4.95(td,J=15.2,3.2Hz,2H),3.63(s,3H),3.60(s,2H).HRMS(ESI-TOF):called for C21H16ClF2N3O2S[M+H]+480.0682,found 480.0807.
实施例19
体外PDE4B酶抑制活性测试
PDE4B酶抑制活性的评价采用了以荧光标记的cAMP为底物与PDE4B1反应,通过检测剩余底物的荧光偏振信号强度,间接测定化合物对酶活性的影响的方法。具体结果如表1所示。
表1实施例中化合物的PDE4B抑制活性
化合物名称 | 1μM抑制率 | 10μM抑制率 |
对照组:Rolipram | 82% | 99% |
I-1 | 14% | 52% |
I-2 | 20% | 61% |
I-3 | 28% | 67% |
I-4 | 58% | 89% |
I-5 | 32% | 74% |
I-6 | 47% | 81% |
I-7 | 18% | 49% |
I-8 | 38% | 78% |
I-9 | 10% | 46% |
I-10 | 75% | 94% |
I-11 | 62% | 84% |
I-12 | 11% | 52% |
I-13 | 13% | 49% |
I-14 | 46% | 91% |
I-15 | 37% | 81% |
I-16 | 25% | 76% |
I-17 | 22% | 65% |
I-18 | 18% | 56% |
如上表所示,本发明的化合物具有良好的PDE4B抑制活性。
实施例20
体外细胞活性TNF-α抑制测试试验
将分离得到的RAW264.7巨噬细胞置于含10%胎牛血清、1%青霉素/链霉素的RPMI1640培养基中,接种于96孔板。各孔加入DMSO溶解的咯利普兰和试验化合物(1uM和10uM),形成对照组与实验组。将接种好的细胞置于37℃,5%CO2饱和湿度的培养箱中孵育,2h后每孔分别加入LPS溶液(0.1μg·mL-1)10μL,再置于CO2培养箱中孵育24h。24h后取出96孔板,吸出各孔培养液至1.5mL离心管中,离心20min,取上清液用于测定TNF-α的含量。具体结果如图1所示,部化合物对TNF-a抑制剂效果较好(p<0.001)。
以上所述仅是本发明的优选实施方式,应当指出:对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (4)
1.一种取代的吲唑杂环类化合物,其特征在于,选自以下化合物之一:
式I中:
W为N、Y为N、Z为C,Y和Z之间为双键,X为NH,取代基X的位置选自W的邻位、对位或间位;
R1选自C1-C6烷基、C2-C6烯基、C2-C6羧基、-CH2CHF2、-CH2CF3或取代苄基中的一种,所述取代苄基中苄基的取代基选自F、Cl、Br、I、CF3、CN、羟基、甲氧基、甲基、氨基、硝基、巯基、羧基、乙烯基、C4-C8直链烷基或支链烷基;R2为芳基或杂环芳基,所述芳基为无取代、单取代或多取代的苯基,单取代或多取代的取代基为卤素、氰基或硝基,所述杂环芳基选自无取代、单取代或多取代的咪唑、噻唑或噻吩,单取代或多取代的取代基选自卤素、氰基或硝基;
R3选自C2-C6羧基、苯基或苄基,所述苯基或苄基为无取代、单取代或双取代,单取代或双取代的取代基选自F、Cl、Br、CF3、CN、羧基。
2.根据权利要求1所述的化合物,其特征在于,选自以下化合物:
3.权利要求1所述化合物或其旋光异构体、对映体、非对映体、外消旋体、外消旋混合物,或者其药学上可接受的盐在制备预防和/或治疗与PDE4B相关疾病的药物中的应用,所述PDE4B相关疾病包括炎症疾病和中枢神经疾病。
4.根据权利要求3所述的应用,其特征在于:所述炎症疾病为慢性阻塞性肺病、哮喘、皮炎、银屑病;所述中枢神经疾病为阿兹海默症、抗焦虑、改善认知。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010703992.XA CN111875594A (zh) | 2020-07-21 | 2020-07-21 | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 |
CN202010703992X | 2020-07-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113563319A CN113563319A (zh) | 2021-10-29 |
CN113563319B true CN113563319B (zh) | 2024-01-12 |
Family
ID=73154584
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010703992.XA Pending CN111875594A (zh) | 2020-07-21 | 2020-07-21 | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 |
CN202110813592.9A Active CN113563319B (zh) | 2020-07-21 | 2021-07-19 | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010703992.XA Pending CN111875594A (zh) | 2020-07-21 | 2020-07-21 | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN111875594A (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111875594A (zh) * | 2020-07-21 | 2020-11-03 | 中国药科大学 | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004073711A2 (fr) * | 2003-02-19 | 2004-09-02 | Exonhit Therapeutics Sa | Methodes impliquant la pde4, compositions et leur criblage pour le traitement de pathologies neurodegeneratives oculaires |
WO2005009438A1 (en) * | 2003-07-25 | 2005-02-03 | Pfizer Limited | Nicotinamide compounds useful as pde4 inhibitors |
WO2005090354A1 (en) * | 2004-03-16 | 2005-09-29 | Glaxo Group Limited | PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS |
CN1694882A (zh) * | 2002-09-16 | 2005-11-09 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
CN1823063A (zh) * | 2003-05-21 | 2006-08-23 | 葛兰素集团有限公司 | 作为磷酸二酯酶抑制剂的喹啉衍生物 |
CN1914205A (zh) * | 2003-12-19 | 2007-02-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
CN111875594A (zh) * | 2020-07-21 | 2020-11-03 | 中国药科大学 | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 |
-
2020
- 2020-07-21 CN CN202010703992.XA patent/CN111875594A/zh active Pending
-
2021
- 2021-07-19 CN CN202110813592.9A patent/CN113563319B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1694882A (zh) * | 2002-09-16 | 2005-11-09 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
WO2004073711A2 (fr) * | 2003-02-19 | 2004-09-02 | Exonhit Therapeutics Sa | Methodes impliquant la pde4, compositions et leur criblage pour le traitement de pathologies neurodegeneratives oculaires |
CN1823063A (zh) * | 2003-05-21 | 2006-08-23 | 葛兰素集团有限公司 | 作为磷酸二酯酶抑制剂的喹啉衍生物 |
WO2005009438A1 (en) * | 2003-07-25 | 2005-02-03 | Pfizer Limited | Nicotinamide compounds useful as pde4 inhibitors |
CN1914205A (zh) * | 2003-12-19 | 2007-02-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
WO2005090354A1 (en) * | 2004-03-16 | 2005-09-29 | Glaxo Group Limited | PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS |
CN111875594A (zh) * | 2020-07-21 | 2020-11-03 | 中国药科大学 | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 |
Also Published As
Publication number | Publication date |
---|---|
CN111875594A (zh) | 2020-11-03 |
CN113563319A (zh) | 2021-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11447453B2 (en) | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | |
JP4059671B2 (ja) | ベンズイミダゾール誘導体 | |
JP2007528362A (ja) | 置換アリールアルカン酸誘導体及びその用途 | |
CN105566276B (zh) | 作为dpp-4抑制剂的苯并六元环衍生物及其应用 | |
WO1997044306A1 (fr) | Derives de chalcone et medicaments les contenant | |
EP2487175A1 (en) | Pharmaceutical product containing aromatic heterocyclic compound | |
WO2014135617A1 (en) | Novel sulfonamide trpa1 receptor antagonists | |
WO2022228544A1 (zh) | 异喹啉酮类化合物及其用途 | |
CN113563319B (zh) | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 | |
CA2240594C (en) | 2,7-substituted octahydro-pyrrolo¬1,2-a|pyrazine derivatives | |
JP2009533441A (ja) | 5‐ヒドロキシトリプタミン‐6リガンドとしての置換ジヒドロ[1,4]オキサジノ[2,3,4‐hi]インダゾール誘導体 | |
JP6612882B2 (ja) | プテリジンジオンモノカルボン酸トランスポータ阻害薬 | |
CN110105286B (zh) | 一种含有脲素骨架的取代杂环类化合物及其制备方法和用途 | |
EP4003337A1 (en) | Aryl hydrocarbon receptor activators | |
JP5893155B2 (ja) | Crth2受容体拮抗薬としての窒素含有縮合環式化合物 | |
US7939520B2 (en) | Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | |
CN117186077A (zh) | 一种3-三唑基甲基-1,3,5-三嗪-2,4-二酮类化合物及其制备方法和应用 | |
JPH08208645A (ja) | キノリン誘導体 | |
CN103933032B (zh) | 作为抗癌药物的吡唑类衍生物的使用方法和用途 | |
CN116640083A (zh) | 一种gpr52调节剂化合物 | |
JP2020531592A (ja) | 重水素化インドールアミン2,3−ジオキシゲナーゼ阻害剤及びその使用 | |
JPH09323975A (ja) | フェニレン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |